Intersect ENT Inc. (XENT) is a Medical/Dental Instruments company listed on NASDAQ. There were no new wire items for XENT in the last 30 days. The most recent was published Jan 23, 2023.
Latest news
25 items- FDAFDA Approval for SINUVA issued to INTERSECT ENT INCSubmission status for INTERSECT ENT INC's drug SINUVA (SUPPL-6) with active ingredient MOMETASONE FUROATE has changed to 'Approval' on 01/20/2023. Application Category: NDA, Application Number: 209310, Application Classification: Labeling
- SECSEC Form POSASR filed by Intersect ENT Inc.POSASR - Intersect ENT, Inc. (0001271214) (Filer)
- SECSEC Form RW WD filed by Intersect ENT Inc.RW WD - Intersect ENT, Inc. (0001271214) (Filer)
- PRNalu Medical, Inc. Names Thomas West President and Chief Executive OfficerCurrent President and CEO, Earl Fender, announces retirement CARLSBAD, Calif., July 14, 2022 /PRNewswire-PRWeb/ -- Nalu Medical, Inc. ("Nalu"), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today that the Board of Directors has appointed Thomas "Tom" West as President and Chief Executive Officer. This leadership appointment is effective on August 8th and follows the decision by Earl Fender, Nalu's current CEO, to retire. Mr. Fender will remain as a consultant to the company for the next 12 months. Mr. West remarked, "I am very excited and honored to be leading Nalu. I believe Nalu's unique system and technology, including the
- SECSEC Form 15-12B filed by Intersect ENT Inc.15-12B - Intersect ENT, Inc. (0001271214) (Filer)
- SECSEC Form S-8 POS filed by Intersect ENT Inc.S-8 POS - Intersect ENT, Inc. (0001271214) (Filer)
- SECSEC Form EFFECT filed by Intersect ENT Inc.EFFECT - Intersect ENT, Inc. (0001271214) (Filer)
- INSIDERSEC Form 4 filed by Hattangadi Neil A4 - Intersect ENT, Inc. (0001271214) (Issuer)
- INSIDERSEC Form 4: Meier Richard A closing all direct ownership in the company4 - Intersect ENT, Inc. (0001271214) (Issuer)
- INSIDERSEC Form 4: Fernandez Reyna M closing all direct ownership in the company4 - Intersect ENT, Inc. (0001271214) (Issuer)
- INSIDERSEC Form 4: Broderick Patrick A closing all direct ownership in the company4 - Intersect ENT, Inc. (0001271214) (Issuer)
- INSIDERSEC Form 4: Gallahue Kieran closing all direct ownership in the company4 - Intersect ENT, Inc. (0001271214) (Issuer)
- INSIDERSEC Form 4 filed by Sandoval Elisabeth4 - Intersect ENT, Inc. (0001271214) (Issuer)
- INSIDERSEC Form 4: West Thomas A. closing all direct ownership in the company4 - Intersect ENT, Inc. (0001271214) (Issuer)
- INSIDERSEC Form 4: Kline Teresa L. closing all direct ownership in the company4 - Intersect ENT, Inc. (0001271214) (Issuer)
- INSIDERSEC Form 4: Lucchese Cynthia L closing all direct ownership in the company4 - Intersect ENT, Inc. (0001271214) (Issuer)
- INSIDERSEC Form 4: Mead Dana G Jr. closing all direct ownership in the company4 - Intersect ENT, Inc. (0001271214) (Issuer)
- SECSEC Form RW filed by Intersect ENT Inc.RW - Intersect ENT, Inc. (0001271214) (Filer)
- SECSEC Form POS AM filed by Intersect ENT Inc.POS AM - Intersect ENT, Inc. (0001271214) (Filer)
- SECSEC Form S-8 POS filed by Intersect ENT Inc.S-8 POS - Intersect ENT, Inc. (0001271214) (Filer)
- SECSEC Form S-8 POS filed by Intersect ENT Inc.S-8 POS - Intersect ENT, Inc. (0001271214) (Filer)
- SECSEC Form S-8 POS filed by Intersect ENT Inc.S-8 POS - Intersect ENT, Inc. (0001271214) (Filer)
- SECSEC Form S-8 POS filed by Intersect ENT Inc.S-8 POS - Intersect ENT, Inc. (0001271214) (Filer)
- SECSEC Form S-8 POS filed by Intersect ENT Inc.S-8 POS - Intersect ENT, Inc. (0001271214) (Filer)
- SECSEC Form S-8 POS filed by Intersect ENT Inc.S-8 POS - Intersect ENT, Inc. (0001271214) (Filer)
XENT FAQ
8 questionsWhat does Intersect ENT Inc. do?
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL and PROPEL Mini, which are steroid releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat...What is the latest news on XENT?
Quantisnow has not tracked any new filings, ratings or press releases for XENT in the last 30 days. The most recent wire item was published on January 23, 2023.Where does XENT stock trade?
Intersect ENT Inc. (XENT) is listed on NASDAQ.What sector and industry is XENT in?
Intersect ENT Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Intersect ENT Inc. go public?
Intersect ENT Inc. (XENT) completed its IPO in 2014.What are analysts saying about XENT?
Across the last 5 analyst actions on Intersect ENT Inc., there was 1 upgrade and 4 downgrades. The most recent action was from SVB Leerink: Market Perform with a $28.25 price target on 2021-08-12. Recent price targets range from $23.00 to $28.25.What companies are similar to XENT?
Notable peers in the same industry include DXCM (DexCom Inc.), SYK (Stryker Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.), MMM (3M Company). Compare XENT side-by-side with any of them on Quantisnow.How can I track XENT on Quantisnow?
Quantisnow aggregates Intersect ENT Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XENT to receive live email and push alerts on every new disclosure.